CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin represent two distinct classes of peptide secretagogues extensively investigated in preclinical endocrinology. This research overview details their complementary biochemical mechanisms, synergistic somatotroph signaling, laboratory handling protocols, and analytical verification standards required for scientific evaluation.
CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin represent two distinct classes of peptide secretagogues extensively investigated in preclinical endocrinology. This research overview details their complementary biochemical mechanisms, synergistic somatotroph signaling, laboratory handling protocols, and analytical verification standards required for scientific evaluation.
The query cjc-1295 no dac + ipamorelin jeep peptides refers to laboratory research formulations combining Modified GRF 1-29 (CJC-1295 No DAC) and Ipamorelin—two complementary growth hormone secretagogues studied for synergistic somatotroph stimulation. These compounds work along separate receptor pathways (GHRH-R and GHS-R) to induce pulsatile growth hormone secretion and downstream IGF-1 expression for preclinical tissue repair research.
In academic and industrial laboratory settings, researchers often evaluate peptide blends to investigate dual-pathway receptor activation. When querying terms like 'jeep peptides' or online supplier listings, primary investigators must distinguish between unverified retail slang and analytical-grade research compounds. High-purity compounds sourced through validated vendors ensure reproducible experimental results in cell culture and animal models.
CJC-1295 No DAC, structurally identified as Modified GRF 1-29, is a synthetic 29-amino acid peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH). By substituting four specific amino acids at positions 2, 8, 15, and 27 relative to native GHRH(1-29), the peptide gains significant resistance to enzymatic cleavage by dipeptidyl peptidase-IV (DPP-IV). This structural modification extends the plasma half-life in vitro and in vivo compared to natural GHRH, while maintaining selective affinity for the GHRH receptor on anterior pituitary somatotrophs.
As a potent GHRH analog, CJC-1295 No DAC functions by binding to the GHRH receptor, initiating a transmembrane signaling cascade via a G-protein-coupled pathway. This stimulates intracellular adenylate cyclase, elevating cyclic adenosine monophosphate (cAMP) levels and triggering protein kinase A (PKA) activation. In preclinical models, this pathway leads to transcription and release of synthesized growth hormone. Unlike CJC-1295 variants containing Drug Affinity Complex (DAC), the 'No DAC' formulation does not covalently bind to serum albumin, resulting in a distinct pulsatile kinetic profile suitable for physiological secretion research. Investigators looking for standalone GHRH analogs can examine our CJC-1295 No DAC product page for detailed chemical specifications.
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) engineered to act as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), commonly known as the ghrelin receptor. Unlike early generation growth hormone-releasing peptides (GHRPs) such as GHRP-2 or GHRP-6, Ipamorelin demonstrates exceptional receptor selectivity. In vitro binding assays show that Ipamorelin selectively stimulates GHS-R1a without inducing significant cross-reactivity at receptors governing adrenocorticotropic hormone (ACTH), cortisol, prolactin, or aldosterone release.
Binding of Ipamorelin to GHS-R1a activates the phospholipase C (PLC) pathway, causing intracellular inositol triphosphate (IP3) accumulation and subsequent mobilization of calcium ions ($Ca^{2+}$) from the endoplasmic reticulum. This localized calcium influx directly promotes the exocytosis of stored growth hormone granules from pituitary somatotrophs. Because Ipamorelin operates independently of the cAMP/PKA pathway utilized by GHRH analogs, its co-administration presents a unique opportunity to study convergent somatotroph signaling. Researchers evaluating individual secretagogues can explore our pure Ipamorelin product page for assay planning.
The co-application of a GHRH analog and a ghrelin receptor agonist produces a well-documented synergistic effect on anterior pituitary hormone release. In rodent models and non-human primate studies, simultaneous stimulation of GHRH-R (via CJC-1295 No DAC) and GHS-R1a (via Ipamorelin) yields a peak growth hormone response substantially greater than the additive mathematical sum of either compound administered in isolation.
Mechanistically, this synergy occurs because GHS-R activation diminishes somatic somatostatin tone—the primary inhibitory brake on GH release—while simultaneously amplifying GHRH-induced cAMP signaling. Consequently, research utilizing a CJC-1295 No DAC + Ipamorelin blend allows scientists to model maximal pulsatile growth hormone discharge without requiring supra-physiological concentrations of a single agent. This dual-action approach is central to contemporary endocrinology research evaluating pituitary reserve capacity and pulsatile kinetics.
Growth hormone released following secretagogue stimulation travels to hepatic and peripheral tissues, where it binds to specific growth hormone receptors (GHR). This binding activates the Janus kinase 2 / signal transducer and activator of transcription 5 (JAK2/STAT5) signaling cascade, driving the transcription and systemic release of Insulin-like Growth Factor 1 (IGF-1). In laboratory models, CJC-1295 No DAC is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research.
Preclinical investigations demonstrate that sustained downstream IGF-1 expression plays a vital role in cellular proliferation, extracellular matrix remodeling, satellite cell activation in skeletal muscle, and collagen synthesis in connective tissue. Researchers studying musculoskeletal regeneration frequently pair secretagogue dynamics with tissue repair peptides like BPC-157 or evaluate broad receptor interactions across our all research peptides catalog to measure systemic repair biomarkers in vitro.
Search phrases such as 'cjc-1295 no dac + ipamorelin jeep peptides' frequently combine standardized chemical nomenclature with specific forum terms, brand queries, or third-party reseller labels. In scientific research, precise chemical definition is paramount. Informal commercial designations or 'gray-market' vendor tags like 'jeep peptides' often lack verified analytical provenance, precise molar concentration data, or lot-specific testing records.
When designing experiments, investigators must prioritize analytical purity over secondary branding. Utilizing unverified peptide sources risks experimental confounding due to potential manufacturing contaminants, sequence mismatches, TFA (trifluoroacetic acid) salt retention, or endotoxin contamination. Conducting systematic review within verified academic repositories via our peptide research hub ensures that researchers base their experimental parameters on standardized, fully characterized reference standards.
To contextualize CJC-1295 No DAC and Ipamorelin within broader secretagogue research, investigators often compare these compounds against other synthetic peptides operating on the somatotrophic axis. Understanding the differences in half-life, receptor affinity, and pulsatility is critical for selecting the appropriate model.
For instance, Tesamorelin is a stabilized 44-amino acid GHRH analog featuring a trans-3-hexenoic acid group, studied extensively for hepatic lipid metabolism and visceral adiposity models. Conversely, Sermorelin represents the truncated native 29-amino acid sequence without structural amino acid substitutions, resulting in a much shorter plasma half-life. A thorough comparative evaluation is available in our technical report on CJC-1295 vs Sermorelin. Furthermore, reviewing our growth hormone secretagogues overview provides additional clarity on how secretagogue classes differ in receptor binding kinetics and duration of action.
Lyophilized CJC-1295 No DAC + Ipamorelin complex must be stored under controlled thermal conditions to maintain peptide integrity. Upon receipt, unopened vials should be kept frozen at -20°C or -80°C for long-term stability. Exposure to repeated freeze-thaw cycles, ambient moisture, or light must be minimized to prevent hydrolysis or oxidation of sensitive residues.
For laboratory reconstitution, researchers should utilize sterile bacteriostatic water (0.9% benzyl alcohol) or laboratory-grade phosphate-buffered saline (PBS). Reconstitution protocols involve directing the solvent down the glass wall of the vial rather than directly onto the lyophilized cake, followed by gentle swirling without vigorous agitation. Reconstituted solution stability should be maintained at 2°C to 8°C and evaluated within a defined experimental window. For large-scale institutional projects requiring high-volume reagents, investigators can access tailored support through our wholesale laboratory portal.
Reliable preclinical research requires rigorous verification of peptide purity and identity. Lower-tier commercial sources often supply peptides without batch-specific analytical documentation. High-purity research materials must undergo strict quality control testing using validated methods prior to laboratory distribution.
At PX1 Research, every production lot is subjected to dual verification testing. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) confirms chemical purity exceeding 98%, while Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular weight and amino acid sequence fidelity. Furthermore, chromogenic Limulus Amebocyte Lysate (LAL) assays verify that endotoxin levels remain strictly below <0.1 EU/mg, preventing cell culture toxicity or non-specific inflammatory responses during in vitro and in vivo studies.
PX1 Research serves as a premier USA-based supplier of analytical-grade peptides tailored strictly for scientific investigation. Our research compounds are manufactured in GMP-compliant facilities and tested by independent ISO 17025 accredited laboratories located within the United States.
We provide transparent, lot-traceable Certificates of Analysis (COAs) for every product line. Each COA includes complete chromatograms, mass spectra, and quantitative endotoxin measurements. Orders ship directly from our climate-controlled California and Arizona facilities with same-day dispatch (Monday through Friday), ensuring structural stability and immediate availability for academic, biotechnology, and institutional research laboratories.
What is CJC-1295 No DAC + Ipamorelin?
It is a combined research peptide formulation comprising Modified GRF 1-29 (a GHRH analog) and Ipamorelin (a selective ghrelin/GHS-R agonist). Together, they are studied in preclinical research to evaluate dual-pathway, synergistic growth hormone release.
How does CJC-1295 No DAC differ from CJC-1295 with DAC?
CJC-1295 No DAC lacks the Drug Affinity Complex (DAC) reactive lysine group. Consequently, it does not bind to circulating albumin, resulting in a shorter half-life (~30 minutes) that produces natural, pulsatile growth hormone spikes rather than continuous, elevated GH exposure.
Why are CJC-1295 No DAC and Ipamorelin studied together in research?
Preclinical studies demonstrate that activating GHRH receptors alongside GHS-R1a receptors yields a synergistic release of growth hormone greater than either compound alone, while simultaneously suppressing somatostatin inhibition.
What quality standards apply to PX1 Research secretagogue blends?
PX1 Research supplies USA-manufactured peptides tested by independent ISO 17025 laboratories. Every lot includes an HPLC/MS COA confirming >98% purity and LAL assay verification confirming endotoxin levels <0.1 EU/mg.
How should lyophilized CJC-1295 No DAC + Ipamorelin be stored in the lab?
Unreconstituted lyophilized powder should be stored at -20°C or -80°C away from light and moisture. Reconstituted solutions using bacteriostatic water should be refrigerated at 2°C to 8°C and used within defined research windows.
What solvent is recommended for reconstituting this peptide blend?
Laboratory reconstitution typically utilizes sterile bacteriostatic water (0.9% benzyl alcohol) or sterile PBS depending on the specific cell culture or assay protocol requirements.
Are CJC-1295 No DAC and Ipamorelin approved for human use or therapeutic administration?
No. CJC-1295 No DAC and Ipamorelin are strictly research chemicals sold for in vitro laboratory and preclinical research use only. They are not for human or veterinary diagnostic, therapeutic, or clinical applications.
Where does PX1 Research ship research compounds from?
All PX1 Research compounds are stocked and shipped directly from climate-controlled fulfillment centers in California and Arizona, offering same-day dispatch for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.